高级检索
当前位置: 首页 > 详情页

Role of Medicinal Plants for Liver-Qi Regulation Adjuvant Therapy in Post-stroke Depression: A Systematic Review of Literature

文献详情

资源类型:
机构: [1]Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, PR China [2]Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, PR China [3]Department of Clinical Research/National Clinical Trials Institute, Sun Yat-sen University Cancer Center, Guangzhou 510060, PR China [4]World Federation of Chinese Medicine Societies, Beijing 100101, PR China [5]Institute of Gastroenterology, Guangzhou University of Chinese Medicine, Guangzhou 510405, PR China [6]Institutes of Science and Development, Chinese Academy of Sciences, Beijing 100190, PR China
出处:
ISSN:

关键词: post-stroke depression MPLR adjuvant therapy meta-analysis systematic review

摘要:
Current evidence demonstrated certain beneficial effects of medicinal herbs as an adjuvant therapy for poststroke depression (PSD) in China; Chai-hu (Chinese Thorowax Root, Radix Bupleuri) is an example of a medicinal plant for Liver-Qi regulation (MPLR) in the treatment of PSD. Despite several narrative reports on the antidepressant properties of MPLR, it appears that there are no systematic reviews to summarize its outcome effects. Therefore, the aim of this review was to assess the effectiveness and safety of MPLR adjuvant therapy in patients with PSD. Seven databases were extensively searched from January 2000 until July 2016. Randomized control trials (RCTs) involving patients with PSD that compared treatment with and without MPLR were taken into account. The pooled effect estimates were calculated based on Cochrane Collaboration's software RevMan 5.3. Finally, 42 eligible studies with 3612 participants were included. Overall, MPLR adjuvant therapy showed a significantly higher effective rate (RR = 1.23; 95% CI = 1.19, 1.27; p< 0.00001) compared to those without. Moreover, the administration of MPLR was superior to abstainers regarding Hamilton Depression Scale (HAMD) score changes after 3 weeks (WMD= - 4.83; 95% CI = - 6.82, - 2.83; p< 0.00001), 4 weeks (WMD= - 3.25; 95% CI = - 4.10, - 2.40; p< 0.00001), 6 weeks (WMD= - 4.04; 95% CI = - 5.24, - 2.84; p< 0.00001), 8 weeks (WMD= - 4.72; 95% CI = - 5.57, - 3.87; p< 0.00001), and 12 weeks (WMD= - 3.07; 95% CI = - 4.05, - 2.09; p< 0.00001). In addition, there were additive benefits in terms of response changes for the National Institutes of Health Stroke Scale (NIHSS) and other self-rating scores. No frequently occurring or serious adverse events were reported. We concluded that there is supporting evidence that adjuvant therapy with MPLR is effective in reducing the depressive symptoms and enhancing quality of life for patients with PSD. More well-designed RCTs are necessary to explore the role of MPLR in the treatment of PSD. Copyright (C) 2016 John Wiley & Sons, Ltd.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 3 区 医学
小类 | 3 区 药物化学 3 区 药学
最新[2023]版:
大类 | 2 区 医学
小类 | 2 区 药物化学 2 区 药学
第一作者:
第一作者机构: [1]Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, PR China [2]Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, PR China
共同第一作者:
通讯作者:
通讯机构: [1]Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, PR China [2]Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, PR China [5]Institute of Gastroenterology, Guangzhou University of Chinese Medicine, Guangzhou 510405, PR China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:52808 今日访问量:0 总访问量:4561 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号